Dr. Epstein-Peterson on the Importance of Treatment Sequencing Decisions in MCL

Zachary Epstein-Peterson, MD, hematologist and oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of treatment sequencing decisions in mantle cell lymphoma (MCL).

Many of the recent advancements made in treating MCL have been due to understanding the biology in patients and the heterogeneity of the disease, Epstein-Peterson says. Since MCL is not a single disease entity, it cannot be treated in the same fashion across all patients, Epstein-Peterson explains, adding that individualizing care for each patient is paramount for their outcomes.

For example, genetic testing in the up-front setting allows for a more tailored approach in patients with TP53 mutations, Epstein-Peterson adds.

The plethora of tools available for the treatment of MCL allows clinicians to better understand how to best sequence and combine therapies, Epstein-Peterson continues. By understanding resistance mechanisms, clinicians can better target them and improve outcomes for patients with MCL, Epstein-Peterson concludes.